TUHURA BIOSCIENCES INC
HURANASDAQπ #3948 by market capEarnings Mar 29 Β· PostUS Equity
$1.25βΌ $0.11 (β8.42%)
Market closed Β· at closeTrack HURA
Get earnings, price moves & breaking news on Telegram
24hβΌ 8.4%
7dβΌ 10.1%
14dβΌ 23.3%
30dβΌ 42.7%
ytdβ² 67.0%
1yβΌ 27.7%
π¦Market Cap
$82M
Small Cap
πRevenue Growth (YoY)
0.0%
Slowing
πGross Margin
0.0%
Thin
π΅FCF Margin
0.0%
Thin
βοΈP/S Ratio
0.0x
Cheap
Otter Score
β
Insufficient data
Trading Snapshot
- Day Range
- $1.25 β $1.34
- 52-Week Range
- $0.41 β $3.43
- Volume (shares)
- 12,668
- Avg Volume (shares)
- β
- Shares Outstanding
- 65.8M
- Next Earnings
- 2027-03-29
Fundamentals Snapshot
- Annual Revenue
- β
- Last Q Revenue
- β
- P/E Ratio
- -2.5
- P/S Ratio
- 0.0x
- EPS (TTM)
- $-0.46
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +13.2%
TUHURA BIOSCIENCES INC
HURAFinancial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isnβt profitable yet.
β$32Mβ² +80.2% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
β$28Mβ² +87.4% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing ownerβs slice.
47.9Mβ² +13.2% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$3MβΌ β$10M YoY
About TUHURA BIOSCIENCES INC
TuHURA Biosciences, Inc. is an immuno-oncology firm that has reached the critical Phase 3 registration stage of clinical development. The company is dedicated to pioneering innovative technologies designed to effectively combat the mechanisms by which cancers develop resistance to existing immunotherapy treatments. Its operations are based in Tampa, Florida.
π¦¦
Otter Score Breakdown
How it's scoredFive components, each rated 1β5β and equally weighted (20%), averaged to a 0β100 score:π Quality β gross marginπ Growth β revenue YoYβοΈ Valuation β P/S ratioβ‘ Momentum β 30-day price changeπ§ Dilution β 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
πQualityβ
β
β
β
β
πGrowthβ
β
β
β
β
βοΈValuationβ
β
β
β
β
π§Dilutionβ
β
β
β
β
Overall Score
Insufficient data
β/100
Analyst Ratings
βConsensus
Buy
10 analysts
Strong Buy2
Buy7
Hold1
Sell0
Strong Sell0
Ratings as of Nov 2026
Latest News & Updates
News unavailable.